01521.HK
Frontage Holdings Corporation
HKSE · Healthcare · Biotechnology · US
HKD 1.30
−0.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 531.0M | 256.7M | 254.9M | 259.9M | 250.4M |
| Cost of Revenue | 389.0M | 187.5M | 185.1M | 181.5M | 161.2M |
| Gross Profit | 142.0M | 69.2M | 69.8M | 78.4M | 89.2M |
| Operating Expenses | |||||
| R&D Expense | 10.2M | 4.3M | 5.6M | 6.0M | 3.9M |
| SG&A Expense | 97.5M | 48.8M | 55.5M | 52.7M | 51.6M |
| General & Admin Expense | 61.8M | 39.2M | 47.0M | 44.6M | 44.4M |
| Selling & Marketing Expense | 11.5M | 7.7M | 8.5M | 8.2M | 7.2M |
| Other Expenses | — | — | (658.0K) | (582.0K) | 127.0K |
| Total Operating Expenses | 107.6M | 53.1M | 60.5M | 58.2M | 55.6M |
| Cost and Expenses | 496.6M | 240.6M | 245.6M | 239.6M | 216.8M |
| Operating Income (EBIT) | 34.3M | 16.1M | 9.3M | 20.2M | 33.6M |
| Non-Operating | |||||
| Interest Income | 4.0M | 289.4K | 812.0K | 1.8M | 498.0K |
| Interest Expense | 15.8M | 7.6M | 9.6M | 7.1M | 3.9M |
| Net Interest Income | (15.7M) | (7.3M) | (8.8M) | (5.3M) | (3.5M) |
| Other Non-Op Income/Expense | (11.0M) | (4.5M) | (6.6M) | (5.6M) | 2.5M |
| Non-Operating Income (excl Interest) | — | — | 1.5M | — | — |
| EBT (Pre-Tax Income) | 23.4M | 11.6M | 2.7M | 14.6M | 36.1M |
| Income Tax Expense | 8.9M | 4.8M | 2.1M | 3.8M | 10.2M |
| Bottom Line | |||||
| Net Income | 14.4M | 6.8M | 791.0K | 10.8M | 25.7M |
| Earnings from Cont. Ops | 14.5M | 6.8M | 619.0K | 10.7M | 25.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 14.4M | 6.8M | 791.0K | 10.8M | 25.7M |
| Per Share | |||||
| Basic EPS | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.01 |
| Diluted EPS | HK$0.01 | HK$0.00 | HK$0.00 | HK$0.01 | HK$0.01 |
| Revenue Per Share | HK$0.26 | HK$0.13 | HK$0.13 | HK$0.13 | HK$0.12 |
| Shares | |||||
| Basic Shares Outstanding | 2.0B | 2.0B | 2.0B | 2.1B | 2.0B |
| Diluted Shares Outstanding | 2.0B | 2.0B | 2.0B | 2.1B | 2.1B |
| Profitability Metrics | |||||
| EBITDA | 92.5M | 41.9M | 35.4M | 45.0M | 54.1M |
| D&A | 58.2M | 25.8M | 27.5M | 24.8M | 20.5M |
| EBIT | 34.3M | 16.1M | 7.9M | 20.2M | 33.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026